2Flasshove M, Meusers P, schutte J,et al. Long-term survival after induction therapy with idarubicin andcytosine arabinoside for de novo acute myeloid leukemia [ J ]. Ann Hematol, 2000,79(10) :533.
3Leoni F, Ciollis S, Nozzoli C, et al.Idarubicin in induction treatment of acute myeloid leukemia in the elderly [ J ]. Heamatologica, 1997,82 (5 Suppl) : 13.
4Giles FJ, Kantar jian HM, Cortes JE, et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patient 50 years or older with adverse karyotype acute myeloid leukemia [J]. J Clin Oncol, 2003,21(9) :1722.
3Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissue:Report of the Clinical Advisory Committee Meeting Airlie House, Virginia, November, 1997. J Cliu Oncol, 1999, 17: 3835-3849.
4Oberg G, Killander A, Bjoremm, M, et al. Long- term follow-up of patients ≥60 years old with acute myeloid leukemia treated with intensive chemotherapy. Enr J Hematol, 2002, 68: 376-381.
5Leoni F, Ciollis S, Nozzoli C, et al. Idanlbicin in induction treatment of acute myeloid leukemia in the elderly. Heamatologica, 1997, 82: 13.
6Giles FJ, Kantarjian HM, Cortes JE, et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idaruhiein in untreated patient 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol, 2003, 21: 1722.
7陆道培,卞寿庚.白血病.北京:中国医药科技出版社,2003:460-461.
8张之南.血液病疗效与诊断标准.第3版.北京:科学出版社,2007:106-107.
9Fukumoto JS,Greenberg PL. Management of patients with higher risk myelodysplastic syndromes. Crit Rev Oncol Hematol, 2005,56 (2) :179-192.
10Saito K, Nakamura Y, Aoyagi M, et al. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AMID and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J Hematol, 2000,71 (3) : 238-244.
